Bio Strategy Advisors is a strategic business consulting firm servicing small and medium-sized Biotech and MedTech companies.
Start-ups: corporate strategy, value creation planning, investment thesis, exit scenarios, strategic partnerships, M&A transactions. Preparation for early-round fund-raising, deck preparation, transaction terms advice, and outreach. Asset pipeline and clinical development program planning.
Later-stage companies: commercial planning, go-to-market models, alliance establishment, licensing and full-service distribution deals, geographical expansion, patient advocacy, market access, and product launch strategy.
Hands-on assistance for Founders/CEO’s/CCO’s on the refinement of Corporate and Commercial Strategy.
Extensive experience in company formation and building of Biotech and MedTech organizations.
Sound advice on fundraising, structuring and negotiating deal terms, definitive agreements, and initial alliance management.
Proven track record on geographical expansion and determining go-to-market models for a solid global footprint, global product launches.
Established contact and relationships with partners for licensing or full-service distribution or 3PLs in the different regions (US, EU, Canada, Asia, LATAM).
Deep expertise in product launches for specialty therapeutics, orphan drugs/rare diseases, and complex devices.
"Bio Strategy Advisors' mission is to facilitate the creation of start-ups in the healthcare space and propelling the growth of biotech companies by providing strategic advisory and contributing more than 25 years of experience in the biopharmaceutical industry. Our passion is to bring innovative technologies or therapies to patients in need around the world."
Founder and Principal, Bio Strategy Advisors LLC
Founding Venture Partner, AccelHUB Venture Partners
Co-Founder, Latinos in Bio
Carolina Alarco has more than 25 years of experience in the biopharmaceutical industry in Cambridge, Massachusetts. Carolina has built a reputation for strategically building markets for rare diseases globally and successfully launching several orphan drugs. She is a dynamic, global, and well-regarded senior executive in the life sciences industry. She has a keen business acumen and relentless focus on execution, consistently delivering results.